DE3680368D1 - Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate. - Google Patents

Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.

Info

Publication number
DE3680368D1
DE3680368D1 DE8686850067T DE3680368T DE3680368D1 DE 3680368 D1 DE3680368 D1 DE 3680368D1 DE 8686850067 T DE8686850067 T DE 8686850067T DE 3680368 T DE3680368 T DE 3680368T DE 3680368 D1 DE3680368 D1 DE 3680368D1
Authority
DE
Germany
Prior art keywords
biologically active
pharmaceutical preparations
factor
human
antihaemophilie
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE8686850067T
Other languages
English (en)
Inventor
Lars-Olof Andersson
Nanna Forsman
Kerstin Ebba Ingrid Larsen
Annelie Birgitta Lundin
Bohdan Pavlu
Inga Helena Sandberg
Karin Margareta Sewerin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Kabi Pharmacia AB
KabiVitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20359353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3680368(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabi Pharmacia AB, KabiVitrum AB filed Critical Kabi Pharmacia AB
Application granted granted Critical
Publication of DE3680368D1 publication Critical patent/DE3680368D1/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D31/00—Protective arrangements for foundations or foundation structures; Ground foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Structural Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Environmental & Geological Engineering (AREA)
  • Hydrology & Water Resources (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Paleontology (AREA)
  • Civil Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE8686850067T 1985-03-05 1986-02-24 Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate. Revoked DE3680368D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof

Publications (1)

Publication Number Publication Date
DE3680368D1 true DE3680368D1 (de) 1991-08-29

Family

ID=20359353

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686850067T Revoked DE3680368D1 (de) 1985-03-05 1986-02-24 Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.

Country Status (10)

Country Link
US (2) US4749780A (de)
EP (1) EP0197901B1 (de)
JP (1) JPS61205219A (de)
AT (1) ATE65505T1 (de)
CA (1) CA1341497C (de)
DE (1) DE3680368D1 (de)
DK (1) DK164282B (de)
HK (1) HK15293A (de)
SE (1) SE8501050D0 (de)
SG (1) SG1893G (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
EP0251843A1 (de) * 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
JP2593500B2 (ja) * 1986-06-24 1997-03-26 ノルデイスク ゲントフテ エー／エス ▲ｖｉｉｉ▼因子フラグメントの凝固活性複合物の製造方法
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
JP3263759B2 (ja) * 1992-04-06 2002-03-11 プレスマスター、トゥール、アーベー クリンプ工具
SK282483B6 (sk) * 1992-10-02 2002-02-05 Genetics Institute, Inc. Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
EP2202242A1 (de) 1996-04-24 2010-06-30 The Regents of The University of Michigan Gegen Inaktivierung resistenter Faktor VIII
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US6143179A (en) * 1996-06-24 2000-11-07 Kerckhoff-Klinik Gmbh Method for the affinity-chromatographic purification of factor VIII
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
EP1038959A1 (de) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
EP1233064A1 (de) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
EP1421539B1 (de) * 2001-06-14 2009-10-28 The Scripps Research Institute Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
WO2003013244A1 (en) 2001-08-03 2003-02-20 The Government Of The United State Of America, As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
SG10201503304RA (en) * 2007-12-27 2015-06-29 Baxter Int Cell culture processes
WO2012151517A1 (en) * 2011-05-05 2012-11-08 Coordinated Program Development, Llc Cochleate compositions and methods of making and using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
EP0148843B2 (de) * 1983-03-21 1994-05-04 Novo Nordisk A/S Antihämophilie-faktor-viii-konzentrat und dessen herstellungsverfahren
FI841281A (fi) * 1983-03-31 1984-10-01 Scripps Clinic Res Ny faktor foer viii koagulenta polypeptider och deras monoklonala antikroppar.
DK165506C (da) * 1984-01-12 1993-04-19 Chiron Corp Proteinpraeparat med koagulationsaktivitet samt fremgangsmaade til fremstilling deraf
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof

Also Published As

Publication number Publication date
EP0197901B1 (de) 1991-07-24
JPH0547524B2 (de) 1993-07-19
DK164282B (da) 1992-06-01
HK15293A (en) 1993-03-05
SG1893G (en) 1993-06-11
DK85786A (da) 1986-09-06
US4877614A (en) 1989-10-31
EP0197901A1 (de) 1986-10-15
ATE65505T1 (de) 1991-08-15
DK85786D0 (da) 1986-02-25
SE8501050D0 (sv) 1985-03-05
JPS61205219A (ja) 1986-09-11
CA1341497C (en) 2006-02-14
US4749780A (en) 1988-06-07

Similar Documents

Publication Publication Date Title
DE3680368D1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
GEP20084347B (en) New derivatives of diphosphonic acid, method for their preparation and medicamentous form containing them
DE3680450D1 (de) Pharmazeutische zubereitungen von metoprolol mit kontrollierter wirkstoffabgabe, verfahren zu ihrer herstellung und verwendung dieser zubereitungen.
EE9900075A (et) 7a-( -aminoalküül)östratrieenid, nende valmistamise meetod, 7a-( -aminoalküül)östratrieene sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
NO903542L (no) Frysetoerket blanding og fremgangsmaate for oral administrering av legemidler, naeringsmidler og biologisk aktive materialer.
ATE111452T1 (de) Tetrahydronaphthalin- und indanderivate, deren herstellung und verwendung für pharmazeutische präparate.
DE3588023D1 (de) Mittel zur Behandlung von Herzerkrankungen.
DK352686A (da) Steril, farmaceutisk tpa-doseringsenhed og fremgangsmaade til fremstilling deraf, beholdersaet indeholdende tpa og doseringsenhedens anvendelse
DE3852440D1 (de) Supraleitendes Mischoxidmaterial und Methode zu dessen Herstellung.
DE3769707D1 (de) Therapeutisches system mit geregelter wirkstoffabgabe.
IS3284A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
FR2601002B1 (fr) Composes aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
HU907959D0 (en) Medical preparations
ES8608490A1 (es) Procedimiento de obtencion de una preparacion farmaceutica en forma de liberacion lenta y que comprende pinacidil (n'-ciano-n-4-piridil-n'-1, 2, 2-trimetil-propilguanidina), opcionalmente junto con otros componentes
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
ATE75938T1 (de) Enantiomere des propafenons enthaltende therapeutische mittel.
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
RU94022543A (ru) Основа лекарственного средства и способ ее изготовления
ATE104847T1 (de) Feste und poroese einzeldosisform, enthaltend perlpartikel und verfahren zu ihrer herstellung.
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: BIOVITRUM AB, STOCKHOLM, SE

8331 Complete revocation